Fundraising Fox

Capricor Therapeutics

NASDAQ: CAPR

Beverly Hills, US · Delaware corporation

Find your way into Capricor Therapeutics

331 people in our graph share verified history with the Capricor Therapeutics team — schools, employers, funds. One of them is your warm intro.

David Mollerunlockedknows Andrew Hamer · together at Harvard Medical School (overlapped)
×10knows the team · via Amgen
knows the team · via University of Otago

Capricor Therapeutics develops cell and exosome-based therapeutics for rare genetic and infectious diseases, with its lead program being Deramiocel, a cell therapy derived from donated heart tissue intended to address muscle degeneration in Duchenne muscular dystrophy and related conditions.

Biotech

Founders & leadership

LMLinda Marban
Linda MarbaninPresident and Chief Executive Officer, DirectorExecutive Officer, Director at Capricor
RSRachel Smith
Rachel SmithinExecutive
KK
Karen KrasneyinExecutive
AB
Anthony BergmannExecutive
AHAndrew Hamer
Andrew HamerinExecutiveAndrew Hamer has over 20 years of experience as a practicing cardiologist and clinical trialist in New Zealand, followed by more than 12 years in biotech development roles. He has led global development initiatives for cardiometabolic products across multiple stages and managed clinical operations, regulatory affairs, and medical affairs functions for both small and large organizations.

Board

JK
Joshua KazamBoard director
DM
David MusketBoard director
LM
Louis ManzoBoard director
EC
Earl Collier, Jr.Board director
LG
Louis GrasmickBoard director
GS
Gregory SchaferBoard director
GD
George DunbarBoard director

Reported raises · per SEC filings

Form D private placements

$20.8M disclosed across 5 of 6 rounds · 1900–2017

▶$3.7MraisedMay 2017 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Frank LitvackDirector
  • Deborah AscheimExecutive Officer
  • Leland GershellExecutive Officer
  • Earl CollierDirector
  • Joshua KazamDirector
  • Louis ManzoDirector
  • Rachel SmithExecutive Officer
  • Karen KrasneyExecutive Officer
  • Linda MarbanExecutive Officer, Director
  • David MusketDirector
  • George DunbarDirector
  • Anthony BergmannExecutive Officer
Offering amount
$3.7M
Amount sold
$3.7M
First sale
May 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$14KraisedMar 2016 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Louis GrasmickDirector
  • Linda MarbanExecutive Officer, Director
  • Deborah AscheimExecutive Officer
  • Louis ManzoDirector
  • Anthony BergmannExecutive Officer
  • Joshua KazamDirector
  • Gregory SchaferDirector
  • Frank LitvackDirector
  • Rachel SmithExecutive Officer
  • Leland GershellExecutive Officer
  • David MusketDirector
  • Earl Collier, Jr.Director
  • Karen KrasneyExecutive Officer
  • George DunbarDirector
Offering amount
$14K
Amount sold
$14K
Placement agents
SC&H Capital
First sale
Mar 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.1MraisedFeb 2015 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Earl Collier, Jr.Director
  • Joshua KazamDirector
  • Karen KrasneyExecutive Officer
  • Gregory SchaferDirector
  • George DunbarDirector
  • David MusketDirector
  • Louis GrasmickDirector
  • Rachel SmithExecutive Officer
  • Frank LitvackDirector
  • Anthony BergmannExecutive Officer
  • Andrew HamerExecutive Officer
  • Louis ManzoDirector
  • Linda MarbanExecutive Officer, Director
Offering amount
$7.1M
Amount sold
$7.1M
Sales commissions
$364.5K
Placement agents
H.C. Wainwright & Co., LLC, SC&H Capital
First sale
Feb 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10MraisedFeb 2015 · 39 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Joshua KazamDirector
  • Louis ManzoDirector
  • Earl Collier, Jr.Director
  • Rachel SmithExecutive Officer
  • Louis GrasmickDirector
  • Karen KrasneyExecutive Officer
  • Gregory SchaferDirector
  • Anthony BergmannExecutive Officer
  • George DunbarDirector
  • Frank LitvackDirector
  • David MusketDirector
  • Linda MarbanExecutive Officer, Director
  • Andrew HamerExecutive Officer
Offering amount
$10M
Amount sold
$10M
Sales commissions
$126.9K
Placement agents
H.C. Wainwright & Co., LLC, SC&H Capital
First sale
Jan 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$32.7KraisedFeb 2014 · 1 investors · Biotechnology
Officers, directors & promoters on the filing
  • Linda MarbanExecutive Officer, Director
  • Frank LitvackDirector
  • Karen KrasneyExecutive Officer
  • Rachel SmithExecutive Officer
  • Andrew HamerExecutive Officer
  • George DunbarDirector
  • Louis ManzoDirector
  • Anthony BergmannExecutive Officer
  • Joshua KazamDirector
  • Gregory SchaferDirector
  • David MusketDirector
  • Louis GrasmickDirector
  • Earl Collier, Jr.Director
Offering amount
$32.7K
Amount sold
$32.7K
First sale
Feb 2014
Incorporated
Corporation, Delaware
Federal exemptions
05
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuitprnewswire.com · Sep 2026CAPR Investment Losses: Capricor Therapeutics Clinical Data Announcement Leads to 64% Stock Drop – BFA Law Reminds Investors of the Pending Securities Fraud Class Actionglobenewswire.com · Aug 2026Deadline Alert: Capricor Therapeutics, Inc. (CAPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuitglobenewswire.com · Aug 2026Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm | Press Releases | kdhnews.comkdhnews.com · Aug 2026CAPR Stock Surges As FDA Path And Analyst Upgrade Align - StocksToTradestockstotrade.com · Aug 2026CAPR Stock Rockets As FDA Extends Review And Cantor Lifts Targettimothysykes.com · Aug 2026

Frequently asked questions

What does Capricor Therapeutics do?
Capricor Therapeutics develops cell and exosome-based therapeutics for rare genetic and infectious diseases, with its lead program being Deramiocel, a cell therapy derived from donated heart tissue intended to address muscle degeneration in Duchenne muscular dystrophy and related conditions.
Who founded Capricor Therapeutics?
Capricor Therapeutics was founded by Linda Marban.
How much funding has Capricor Therapeutics raised?
Capricor Therapeutics has disclosed $20.8M raised across 5 of its 6 known rounds.
Where is Capricor Therapeutics headquartered?
Capricor Therapeutics is headquartered in Beverly Hills, US.